Comparative Pharmacology
Head-to-head clinical analysis: IPLEX versus KEPIVANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IPLEX versus KEPIVANCE.
IPLEX vs KEPIVANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.
0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.
60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.
None Documented
None Documented
Terminal elimination half-life of 10-12 hours after subcutaneous administration, supporting twice-daily dosing.
Terminal elimination half-life is approximately 4.5 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), half-life is prolonged up to 2-fold, requiring dose adjustment. The half-life supports once-daily dosing for 3 consecutive days before chemotherapy.
Renal excretion of intact IGF-I and its metabolites; approximately 70% eliminated via kidneys, with 30% biliary/fecal.
Primarily renal; approximately 90% of the dose is excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Growth Factor
Growth Factor